VolitionRx Limited (NYSE American: VNRX) has announced the publication of the first peer-reviewed paper detailing its proprietary Capture-Seq liquid biopsy technology, which the company says is the first to isolate and analyze more than 99% pure circulating tumor-derived DNA (ctDNA). This breakthrough addresses a longstanding challenge in liquid biopsy: separating cancer-derived DNA from the overwhelming background of healthy cell-free DNA. By doing so, the technology creates highly enriched tumor DNA datasets that can be used for cancer detection and monitoring.
The publication describes a two-step process that combines physical sample enrichment with bioinformatic filtering to produce ctDNA sequencing datasets with purity exceeding 99%. According to the company, early validation studies demonstrated strong cancer detection results, including no false positives in initial cohorts and high detection rates for early-stage cancers. Additional blinded studies have also produced encouraging findings, suggesting the technology's potential clinical utility.
VolitionRx is currently conducting technical evaluations with potential licensing partners and estimates that the technology addresses annual market opportunities of approximately $23 billion for multi-cancer early detection and more than $13 billion for minimal residual disease applications. These figures underscore the significant commercial potential of the technology, which could transform cancer diagnostics by enabling earlier detection and more precise monitoring of treatment response.
The company is advancing larger validation studies, working with oncology key opinion leaders, and expanding patent protection for the technology as it explores commercialization opportunities. This publication marks a critical step in establishing the credibility of Capture-Seq and could pave the way for its adoption in clinical settings.
VolitionRx is a multinational company focused on advancing the science of epigenetics, dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection and monitoring. The company's research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and an office in London. For more information, visit the company's website at https://volition.com/.
The full press release can be viewed at https://ibn.fm/nuJEs.
